Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions

The IDH1/2 gene mutations, ATRX loss/mutation, 1p/19q status, and MGMT promoter methylation are increasingly used as prognostic or predictive biomarkers of gliomas. However, the effect of their combination on radiation therapy outcome is discussable. Previously, we demonstrated that the IDH1 c.G395A...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszkowski, Krzysztof, Furtak, Jacek, Zurawski, Bogdan, Szylberg, Tadeusz, Lewandowska, Marzena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133876/
https://www.ncbi.nlm.nih.gov/pubmed/27834917
http://dx.doi.org/10.3390/ijms17111876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133876/
https://www.ncbi.nlm.nih.gov/pubmed/27834917
http://dx.doi.org/10.3390/ijms17111876

Ejemplares similares